Global Smart Pills Market Size Grows at a CAGR of 11.38%

Introduction

Straits Research released its highly anticipated report, “Smart Pills Market Size & Outlook, 2026-2034.” According to the study, the global smart pills market size is valued at USD 2.57 billion in 2025 and is projected to expand to USD 6.76 billion by 2034, registering a compound annual growth rate (CAGR) of 11.38%.

Market Dynamics

The market growth is primarily attributed to the increasing prevalence of chronic conditions, such as colon cancer is driving the demand for advanced diagnostic tools. For example, in July 2024, as per the data reported in the National Library of Medicine, the PillCam COLON 2 system, developed by Medtronic, is a smart pill designed for colon cancer screening. This ingestible capsule contains a small camera that captures images of the colon as it travels through the gastrointestinal tract. Such a factor highlights the growing importance of smart pills in modern healthcare and their potential to transform disease management strategies. The high cost of devices and procedures, which limits adoption, especially in developing regions, limits the market growth. The advanced imaging technology, embedded sensors, and data analysis systems significantly increase overall costs, making smart pills less accessible for patients and healthcare facilities with constrained budgets. Moreover, the incorporation of AI into smart pill technologies presents a significant market opportunity by enabling advanced data analytics, personalized treatment, and predictive diagnostics. For example, in January 2025, Proteus Digital Health announced the launch of its AI-enabled smart pill platform that monitors patient medication adherence and predicts potential complications in real time. Such innovation highlights the potential of AI integration to enhance patient outcomes and drive wider adoption of smart pill technologies.

Market Highlights

• Indication: The Celiac Disease segment dominated the market in 2025, with a revenue share of 33.18%.
• Application: The Drug Delivery segment is expected to witness the highest CAGR (12.96%) during the forecast period. 
• End User: The Diagnostic Centers segment dominated the market in 2025, fuelled by the increasing demand for specialized, non-invasive diagnostic services, rapid adoption of capsule endoscopy technologies, and the ability to provide faster and more accurate gastrointestinal assessments.
• Regional Insights: North America dominates the market with 52% share, fuelled by the adoption of advanced diagnostic technologies. 

Competitive Players

1. Medtronic
2. Otsuko America Pharmaceutical, Inc.
3. Olympus America
4. CapsoVision, Inc
5. Pentax Medical
6. BDD Ltd
7. JINSHAN Science & Technology 
8. etectRx
9. INTROMEDIC 
10. BodyCAP
11. Check-Cap Ltd.
12. Abbott
13. GE HealthCare
14. Bio-Images & Medimetrics
15. RF Co., Ltd.
16. Tenovi
17. Koninklijke Philips N.V.,
18. Proteus Digital Health, Inc.
19. JINSHAN Science & Technology
20. Novartis AG
21. Others

Recent Developments

Segmentation

1. By Indication (2026-2034)
   1. Celiac Disease
   2. Small Bowel Diseases
   3. Colon Cancer
   4. Others
2. By Application (2026-2034)
   1. Capsule Endoscopy
   2. Drug Delivery
   3. Vital Sign Monitoring
3. By End User (2026-2034)
   1. Hospitals and Clinics
   2. Diagnostic Centers